Introduction
============

Detailing the planned methods for conducting a systematic review in advance of commencing the review is essential in order to minimise a range of potential biases ^[@ref-1],\ [@ref-2]^. The plan, set out in a protocol, should ideally be made available in the public domain to facilitate transparency ^[@ref-3],\ [@ref-4]^. In addition, registration of key protocol details is encouraged as best practice in reporting guidelines ^[@ref-5],\ [@ref-6]^ by publishers like the British Medical Journal (BMJ), Public Library of Science (PLoS), and BioMed Central (BMC), and is mandated in their instructions to authors by journals such as BMC Systematic Reviews, BMJ, BMJ Open, PLoS One, and National Institute for Health Research (NIHR) journals.

There are a number of options for putting systematic review protocols into the public domain, such as publication in open access journals like BMC Systematic Reviews and uploading to open data repositories like the Open Science Framework (OSF) ( <https://osf.io/registries/discover?q=protocols>). PROSPERO ( <https://www.crd.york.ac.uk/prospero/>) is a facility for registering key methodological details in advance of carrying out a review. Registration on PROSPERO requires completion of an internationally agreed minimum dataset for a systematic review protocol ^[@ref-7],\ [@ref-8]^. Registrants also have the option of uploading their protocol or providing a hyperlink to it.

PROSPERO remains the only free, open access registry of systematic review protocols, making it a single searchable source of the protocols of on-going and completed reviews. Uptake of registration has increased exponentially and by the end of 2019 there were over 60,000 registrations in PROSPERO. There is evidence that considerably more systematic reviews are registered in PROSPERO than have peer-reviewed protocols published. In 2016, 1058 records were accepted by PROSPERO; in the same time period, only 404 published systematic review protocols were identified ^[@ref-3]^. Another study reported identifying 20,814 non-Cochrane systematic review protocols from web scraping PROSPERO and bibliographic database searches. Of these, 924 were only published in journals, 807 were published in journals and registered in PROSPERO and 19,890 were only available as a record in PROSPERO ^[@ref-9]^. There is further evidence from Ge *et al* (2018) that of the non-Cochrane reviews registered in PROSPERO, only 3% or 4% have a published protocol ^[@ref-9],\ [@ref-10]^. This means that for a large number of reviews a PROSPERO record is likely to be the only source providing details of the planned methods.

Published protocols and registration records aim to provide transparency in the review process by allowing public access to the key pre-specified elements for the conduct of a review. One of the stated aims of PROSPERO is to facilitate comparison between planned review methods and reported results ^[@ref-8]^. Such a comparison enables peer reviewers and other readers of the final review to assess for themselves the potential for bias in the findings. There is also a steadily growing body of research using PROSPERO records to assess the risk of biases in final review reports ^[@ref-10]--\ [@ref-15]^. Given this reliance on the information provided in PROSPERO records, it is important to understand the level of detail provided in records. The focus of this study was on the stated aim of PROSPERO to reduce the opportunity for bias by enabling comparison of the completed review with what was planned in the protocol ^[@ref-8]^.

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Protocols (PRISMA-P) were developed through expert consensus using internationally compiled datasets such as PROSPERO and SPIRIT ^[@ref-4],\ [@ref-6]^.

Key methodological aspects of a protocol are mandated for registration in PROSPERO; other items, mainly administrative fields, are optional ^[@ref-7],\ [@ref-8]^. Submissions for registration are not subject to any form of peer review or critical appraisal, they are simply checked for sense but not methodological rigor. Therefore, there is the possibility that PROSPERO records do not provide all the necessary information identified by the PRISMA-P guidelines to enable comparison with the completed systematic review. The registration record may be the only place where *a priori* methods are available for users, in particular peer reviewers, to check for potential issues such as selection, outcome reporting and publication biases. This study investigated the extent to which records in PROSPERO, where no protocol or other information was available, comply with each of the items for reporting of protocols set out in the PRISMA-P guidelines.

Methods
=======

A random sample of PROSPERO registration records were assessed against the systematic review protocol reporting criteria set out in the PRISMA-P 2015 checklist ^[@ref-4]^. Key methods are provided here with further details available in the protocol for this study, which was prepared and made publicly available on the OSF, 17 March 2020 ( *Extended data* ^[@ref-16]^).

Study sample of PROSPERO records
--------------------------------

A dataset of non-Cochrane PROSPERO records was provided by Metaxis, the software managers of PROSPERO. Records of reviews defined by the record holder as a health intervention registered on or between 1 January 2018 and 31 December 2018, were identified.

Cochrane reviews, reviews of animal studies, non-intervention reviews as identified in PROSPERO, i.e. Diagnostic accuracy, Prognostic factors, Prevention, Epidemiological reviews relevant to health and social care, Public health, Service delivery in health and social care, Methodological reviews, reviews of reviews, and synthesis of qualitative studies, were all excluded as PROSPERO and PRISMA-P were developed for reviews of interventions. Only records with no evidence from the registration record of other protocol related information, for example in a published protocol or other links in the PROSPERO record, were included and we restricted the data set to those records with a single registry entry.

Records from the calendar year 2018 were used to allow time for dissemination and adoption of the PRISMA-P guidelines published in 2015. A sample of 20% of these records was randomly selected using simple random sampling for assessment against the PRISMA-P reporting criteria.

Assessment tool and scoring
---------------------------

The PRISMA-P checklist recommends 17 numbered items, with nine subdivisions, totalling 26 items be reported in a systematic review protocol ^[@ref-4]^. Seven of the 26 items were excluded from the assessment as they would always or never meet registration requirements in PROSPERO. For example, registration is implicit for a record accepted in PROSPERO, and there is no field for author contributions or sponsor role so these would never be reported. The study assessment tool, developed specifically for this study as a Google Form, therefore contained 19 of the PRISMA-P items. Where the PRISMA-P description for an item specified more than one piece of information, the individual elements were listed as subsets of the items ^[@ref-4],\ [@ref-6]^. This list contained 63 elements to be reported.

Where an item was reported or not applicable, a score of 1 was assigned. Where the information was not reported this scored 0. The maximum possible overall score for the PRISMA-P listed items was 19 per record. Scores for the breakdown of individual elements within the items was also reported, the maximum possible score was 63 per record.

Assessment procedure
--------------------

The researchers undertaking the assessments (AB, ASM, AM, SJ, SC, SG) familiarised themselves with both PRISMA-P papers ^[@ref-4],\ [@ref-6]^. All had previously received training in systematic review methods and/or authored at least one systematic review. The draft assessment form and accompanying guidance notes were revised and finalised during a training session and piloted with the aim of achieving greater than 90% agreement.

Two researchers independently compared the information provided in each PROSPERO record with the relevant items in the study assessment tool. Options for decisions were: Reported (information provided as per PRISMA-P requirements); Not reported (some or all information not provided); and, Not applicable (where an item was not relevant to an individual record, e.g. a meta-analysis was not planned).

Records were randomly assigned to assessors by first creating a list of the sampled record unique identification numbers and dividing the list into 14 blocks of approximately equal size, with each block being assigned a colour. A copy of this list together with the block configuration was then placed alongside the original list. Seven sub-lists were then created by randomly selecting a block from the first list and a block from the second list, such that blocks of the same colour were not in the same sub-list, and each colour appeared in two sub-lists. Each sub-list was then randomly assigned to an assessor.

It was not feasible to blind the researchers to the authors of registrations in PROSPERO. None of the assessors were authors of included registrations. On completion of the pilot assessments and the full set of records, disagreements were resolved through discussion or recourse to a third researcher.

The assessment form and the guidance notes are available on the OSF ( *Extended data* ^[@ref-16]^).

Analysis
--------

The primary outcome for this study was the compliance of PROSPERO registration records to PRISMA-P reporting items. This was measured by the total mean score allocated by the two independent assessors to each of the 19 items assessed (maximum possible score 19) for each record and by the total mean score for the individual elements within items (maximum possible score 63). Overall scores for the assessed dataset, scores by the 19 PRISMA-P items and by the 63 elements were the planned outcome measures.

For the eligible 2018 records that were assessed and those not assessed, demographic data for month of registration, funding/sponsor, planned meta-analysis, number of authors, stage of review at registration, topic and country of review were to be reported. Comparisons to identify any association between records registered before or after screening started; whether a meta-analysis was planned or not; and whether a review was funded/sponsored or not and completeness of reporting of items were planned.

Deviations from protocol
------------------------

During piloting of the assessment form, it became clear that it would not be possible to assess records for PRISMA-P item 5a Sources and 5b Sponsor. This would have required separating sources of financial support from sponsorship or any other form of support as reported in the single PROSPERO field, which was not possible. This item was therefore removed from the assessment form. Instead, a series of regular expression patterns was compared to the list of eligible records to identify those where the record contained any indication of funding/ sponsorship/support or indicated there was none. These data were used in the presentation of demographics and subgroup comparison.

Results
=======

The PROSPERO dataset contained 5,313 records for reviews of health interventions first accepted in 2018 (excluding Cochrane and reviews of animal studies). Applying the other study inclusion/exclusion criteria resulted in 2,194 eligible registration records. The randomly selected sample of 20% for assessment included 439 records. During assessment, six records were excluded, for not meeting the inclusion criteria (4), being a duplicate (1) or no longer available on PROSPERO (1). Assessments were therefore carried out on 433 PROSPERO records. A flow chart of record selection is shown in [Figure 1](#f1){ref-type="fig"}.

![Flow chart of record sample identification.](f1000research-9-27788-g0000){#f1}

Agreement following initial piloting of the assessment form was 87%; after further discussions and revision of the assessment guidance notes and form a second pilot achieved 92% agreement. For all the records assessed, agreement between researchers was 90%, all differences were resolved through discussion or referral to a third researcher.

Demographic details of the sample of PROSPERO records selected for assessment and those not assessed are provided in [Table 1](#T1){ref-type="table"}. The number of authors listed ranged between one and 17, with the exception of a single record, included in the assessed sample, where 47 authors were listed. The eligible sample for 2018 included records from 67 different countries: 20 records listed two countries and 15 listed between three and nine countries involved in the review. There were no substantial differences between the data sets in the month of registration; whether any details of funding and/or sponsorship were provided; whether a meta-analysis was planned or not; the number of authors listed per record; stage of review at registration; topic of review or country involved in undertaking the review.

###### Demographic details of non-sample set and sample set of the eligible 2018 PROSPERO records.

  -------------------------------------------------------------------------------------------------------------------------------------------
  Demographic                                                Records for assessment\                       Records not assessed\   
                                                             (n = 439)                                     (n = 1755)              
  ---------------------------------------------------------- --------------------------------------------- ----------------------- ----------
  **Month of registration n (%)**                            *January*                                     45 (10)                 168 (10)

  *February*                                                 32 (7)                                        141 (8)                 

  *March*                                                    25 (6)                                        100 (6)                 

  *April*                                                    35 (8)                                        122 (7)                 

  *May*                                                      16 (4)                                        110 (6)                 

  *June*                                                     36 (8)                                        151 (8)                 

  *July*                                                     54 (12)                                       188 (11)                

  *August*                                                   56(12)                                        200 (11)                

  *September*                                                31 (7)                                        151 (9)                 

  *October*                                                  37 (8)                                        138 (8)                 

  *November*                                                 37 (8)                                        160 (9)                 

  *December*                                                 35 (8)                                        126 (7)                 

  **Funding/support indicated n (%)**                        386 (88)                                      1572 (90)               

  **Meta-analysis planned n (%)**                            253 (58)                                      1064 (61)               

  **Number of listed authors (mean, range)**                 4.1 (0 -- 47 [\*](#TFN1){ref-type="other"})   3.9 (0 -- 17)           

  **Stage of review [\*\*](#TFN2){ref-type="other"}**\       *Not Started*                                 96 (22)                 385 (22)
  **n (%)**                                                                                                                        

  *Searches Start*                                           65(15)                                        283 (16)                

  *Searches Complete*                                        12 (3)                                        57 (3)                  

  *Pilot Selection Start*                                    56 (13)                                       252 (14)                

  *Pilot Selection Complete*                                 16 (4)                                        50 (3)                  

  *Screening Start*                                          80 (19)                                       285 (16)                

  *Screening Complete*                                       13 (3)                                        56 (3)                  

  *Extraction Start*                                         93 (21)                                       376 (21)                

  *Extraction complete*                                      2 (0)                                         8 (1)                   

  **Topic of review [\*\*\*](#TFN3){ref-type="other"}**\     *Alcohol/substance misuse/abuse*              12 (3)                  28 (2)
  **n (%)**                                                                                                                        

  *Blood and immune system*                                  13 (3)                                        90 (5)                  

  *Cancer*                                                   42 (10)                                       182 (10)                

  *Cardiovascular*                                           61 (14)                                       220 (13)                

  *Care of the elderly*                                      16 (4)                                        72 (4)                  

  *Child health*                                             31 (7)                                        139 (8)                 

  *Complementary therapies*                                  43 (10)                                       178 (10)                

  *Crime and justice*                                        0 (0)                                         2 (0)                   

  *Dental*                                                   30 (7)                                        138 (8)                 

  *Digestive system*                                         34 8)                                         127 (7)                 

  *Ear, nose and throat*                                     7 (2)                                         27 (2)                  

  *Education*                                                10 (2)                                        23 (1)                  

  *Endocrine and metabolic disorders*                        35 (8)                                        144 (8)                 

  *Eye disorders*                                            3 (1)                                         16 (1)                  

  *General interest*                                         5 (1)                                         29 (2)                  

  *Genetics*                                                 3 (1)                                         5 (0)                   

  *Health inequalities/health equity*                        3 (1)                                         8 (1)                   

  *Infections and infestations*                              22 (5)                                        97 (6)                  

  *International development*                                0 (0)                                         2 (0)                   

  *Mental health and behavioural conditions*                 51 (12)                                       129 (7)                 

  *Musculoskeletal*                                          70 (16)                                       253 (14)                

  *Neurological*                                             44 (10)                                       208 (12)                

  *Nursing*                                                  11 (3)                                        45 (3)                  

  *Obstetrics and gynaecology*                               23 (5)                                        101 (6)                 

  *Oral health*                                              21 (5)                                        100 (6)                 

  *Palliative*                                               4 (1)                                         16 (1)                  

  *Perioperative care*                                       14 (3)                                        81 (5)                  

  *Physiotherapy*                                            36 (8)                                        129 (7)                 

  *Pregnancy and childbirth*                                 13 (3)                                        60 (3)                  

  *Public Health*                                            0 (0)                                         0 (0)                   

  *Rehabilitation*                                           43 (10)                                       173 (10)                

  *Respiratory disorders*                                    16 (4)                                        87 (5)                  

  *Service delivery*                                         0 (0)                                         0 (0)                   

  *Skin disorders*                                           12 (3)                                        40 (2)                  

  *Social care*                                              0 (0)                                         2 (0)                   

  *Surgery*                                                  49 (11)                                       209 (12)                

  *Tropical medicine*                                        0 (0)                                         0 (0)                   

  *Urological*                                               20 (5)                                        71 (4)                  

  *Wounds, injuries and accidents*                           11 (3)                                        70 (4)                  

  *Violence and abuse*                                       3 (1)                                         10 (1)                  

  **Country of review [\*\*\*](#TFN3){ref-type="other"}**\   *Australia*                                   33 (8)                  143 (8)
  **n (%)**                                                                                                                        

  *Brazil*                                                   53 (12)                                       224 (13)                

  *Canada*                                                   38 (9)                                        121 (7)                 

  *China*                                                    100 (23)                                      414 (24)                

  *England*                                                  46 (10)                                       163 (9)                 

  *Germany*                                                  13 (3)                                        40 (2)                  

  *Italy*                                                    14 (3)                                        62 (4)                  

  *Netherlands*                                              13 (3)                                        51 (3)                  

  *Spain*                                                    13 (3)                                        39 (2)                  

  *USA*                                                      48 (11)                                       160 (9)                 

  *57 other countries*                                       127 (29)                                      562 (32)                
  -------------------------------------------------------------------------------------------------------------------------------------------

*\* the record with 47 authors was a single outlier: range excluding this record was 0-15*

*\*\* details for three records were not available on PROSPERO*

*\*\*\* all items reported by authors included; therefore totals are more than the number of records*

None of the PROSPERO records assessed against the eligibility criteria reported on all elements in each of the items recommended for a systematic review protocol in the PRISMA-P guidelines. The mean total score for individual PROSPERO records, where 1 point was gained for each of the 19 items in the PRISMA-P checklist, was 4.8, the standard deviation 1.8, the median 4, and range 2 to 11. Considering all items across all the assessed records, only 25% (2081/8227) of the items were scored as reported.

The mean total score for individual PROSPERO records where 1 point was gained for each of the 63 elements of the PRISMA-P reporting guidelines was 33.4, the standard deviation 5.8, the median 33 and the range 18--47. Overall, 53% (14,469/27,279) of the elements were considered as reported.

Scoring for 19 PRISMA-P items
-----------------------------

The highest scoring item was PRISMA-P 1b which requires the protocol to be identified as to whether it is an update of a review; the high score was the result of this being a not-applicable item for 423 (98%) of the 433 records ( [Table 2](#T2){ref-type="table"}). Eligibility criteria (study design, setting, population, intervention, comparator, outcomes) was the next highest scoring item with 386 (89%) reporting all of these elements. Selection process (214, 49%), describing the criteria under which study data will be quantitatively synthesized (200, 46%), and describing the type of summary planned if quantitative synthesis is not appropriate (227, 52%) were the next highest scoring of the 19 items assessed.

The scores by PRISMA-P item and by breakdown of items are presented in [Table 2](#T2){ref-type="table"}. The full dataset with assessment outcomes and scores for individual records, and the subgroup analyses scoring are available on the OSF ( *Underlying data* ^[@ref-16]^).

###### Assessment scores by item and breakdown for 433 PROSPERO records.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  PRISMA-P reporting item                                                 Reported\    Not\       Breakdown of items                                          Reported   Not\       Not\
                                                                          or not\      reported                                                                          reported   applicable
                                                                          applicable                                                                                                
  ----------------------------------------------------------------------- ------------ ---------- ----------------------------------------------------------- ---------- ---------- ------------
  Section 1 Administrative information                                                                                                                                              

  1a. Identification in the title:\                                       22 (5)       411 (95)   Identify the report as a\                                   22 (5)     411 (95)   /
  Identify the report as a protocol of\                                                           protocol                                                                          
  a systematic review                                                                                                                                                               

  Identify the report as a\                                               342 (79)     91 (21)    /                                                                                 
  systematic review                                                                                                                                                                 

  1b. Update: If the protocol is\                                         424 (98)     9 (2)      Identify the report as an\                                  1 (0)      9 (2)      423 (98)
  for an update of a previous\                                                                    update                                                                            
  systematic review                                                                                                                                                                 

  Section 2 Introduction                                                                                                                                                            

  6\. Rationale: Describe the\                                            38 (9)       395 (91)   Rationale described                                         44 (10)    389 (90)   /
  rationale for the review in the\                                                                                                                                                  
  context of what is already known                                                                                                                                                  

  Context provided [\*](#TFN4){ref-type="other"}                          108 (25)     325 (75)   /                                                                                 

  7\. Objectives: Provide an explicit\                                    134 (31)     299 (69)   Population                                                  397 (92)   36 (8)     /
  statement of the question(s) the\                                                                                                                                                 
  review will address with reference\                                                                                                                                               
  to participants, interventions,\                                                                                                                                                  
  comparators, and outcomes\                                                                                                                                                        
  (PICO) [\*](#TFN4){ref-type="other"}                                                                                                                                              

  Intervention                                                            416 (96)     17 (4)     /                                                                                 

  Comparator                                                              142 (33)     264 (61)   27 (6)                                                                            

  Outcomes                                                                237 (55)     196 (45)   /                                                                                 

  Section 3 Methods                                                                                                                                                                 

  8\. Eligibility criteria: Specify the\                                  386 (89)     47 (11)    Study design specified [\*](#TFN4){ref-type="other"}        427 (99)   6 (1)      /
  study characteristics (e.g., PICO,\                                                                                                                                               
  study design, setting, time frame)\                                                                                                                                               
  and report characteristics (e.g.,\                                                                                                                                                
  years considered, language,\                                                                                                                                                      
  publication status) to be used as\                                                                                                                                                
  criteria for eligibility for the review [\*](#TFN4){ref-type="other"}                                                                                                             

  Setting (condition or\                                                  410 (95)     23 (5)     /                                                                                 
  domain) specified [\*](#TFN4){ref-type="other"}                                                                                                                                   

  Population [\*](#TFN4){ref-type="other"}                                429 (99)     4 (1)      /                                                                                 

  Intervention [\*](#TFN4){ref-type="other"}                              428 (99)     5 (1)      /                                                                                 

  Comparator [\*](#TFN4){ref-type="other"}                                392 (91)     14 (3)     27 (6)                                                                            

  Outcome(s) [\*](#TFN4){ref-type="other"}                                424 (98)     9 (2)      /                                                                                 

  9\. Information sources: Describe\                                      2 (1)        431 (99)   Electronic database(s)\                                     431 (99)   2 (1)      /
  all intended information sources\                                                               named                                                                             
  (e.g., electronic databases,\                                                                                                                                                     
  contact with study authors, trial\                                                                                                                                                
  registers, or other grey literature\                                                                                                                                              
  sources) with planned dates of\                                                                                                                                                   
  coverage [\*](#TFN4){ref-type="other"}                                                                                                                                            

  Grey literature sources                                                 100 (23)     333 (77)   /                                                                                 

  Study registries                                                        289 (67)     144 (33)   /                                                                                 

  Contact with study authors\                                             27 (6)       406 (94)   /                                                                                 
  planned or statement that\                                                                                                                                                        
  contact not planned                                                                                                                                                               

  Other: e.g. hand searching\                                             152 (35)     281 (65)   /                                                                                 
  reference lists of included\                                                                                                                                                      
  studies                                                                                                                                                                           

  Planned search dates                                                    238 (55)     195 (45)   /                                                                                 

  10\. Search strategy: Present draft\                                    75 (17)      358 (83)   Draft search strategy\                                      91 (21)    342 (79)   /
  of search strategy to be used for\                                                              provided                                                                          
  at least one electronic database,\                                                                                                                                                
  including planned limits, such that\                                                                                                                                              
  it could be repeated                                                                                                                                                              

  Search terms given alone                                                100 (23)     242 (56)   91 (21)                                                                           

  Approach to limits/\                                                    332 (77)     101 (23)   /                                                                                 
  restrictions reported\                                                                                                                                                            
  e.g. language or dates/\                                                                                                                                                          
  statement of no limits [\*](#TFN4){ref-type="other"}                                                                                                                              

  11a. Data management: Describe\                                         17 (4)       416 (96)   Software named/type\                                        56 (13)    377 (87)   /
  the mechanism(s) that will be\                                                                  indicated [\*](#TFN4){ref-type="other"}                                           
  used to manage records and data\                                                                                                                                                  
  throughout the review                                                                                                                                                             

  De-duplication planned                                                  42 (9)       391 (91)   /                                                                                 

  11b. Selection process: State\                                          214 (49)     219 (51)   Initial screening process\                                  232 (54)   201 (46)   /
  the process that will be used\                                                                  described [\*](#TFN4){ref-type="other"}                                           
  for selecting studies (e.g., two\                                                                                                                                                 
  independent reviewers) through\                                                                                                                                                   
  each phase of the review (i.e.,\                                                                                                                                                  
  screening, eligibility, and inclusion\                                                                                                                                            
  in meta-analysis)                                                                                                                                                                 

  Full paper screening\                                                   219 (51)     214 (49)   /                                                                                 
  process described [\*](#TFN4){ref-type="other"}                                                                                                                                   

  11c. Data collection process:\                                          50 (12)      383 (88)   Data extraction form                                        169 (39)   264 (61)   /
  Describe planned method of\                                                                                                                                                       
  extracting data from reports\                                                                                                                                                     
  (e.g., piloting forms, done\                                                                                                                                                      
  independently, in duplicate),\                                                                                                                                                    
  any processes for obtaining\                                                                                                                                                      
  and confirming data from\                                                                                                                                                         
  investigators [\*](#TFN4){ref-type="other"}                                                                                                                                       

  Data extraction process\                                                258 (60)     175 (40)   /                                                                                 
  described                                                                                                                                                                         

  Obtain missing data                                                     76 (18)      357 (82)   /                                                                                 

  12\. Data items: List and define all\                                   6 (1)        427 (99)   List of data for extraction [\*](#TFN4){ref-type="other"}   219 (51)   214 (49)   /
  variables for which data will be\                                                                                                                                                 
  sought (e.g., PICO items, funding\                                                                                                                                                
  sources), any pre-planned data\                                                                                                                                                   
  assumptions and simplifications                                                                                                                                                   

  Variables defined [\*](#TFN4){ref-type="other"}                         29 (7)       404 (93)   /                                                                                 

  Any data assumptions\                                                   17 (4)       416 (96)   /                                                                                 
  reported                                                                                                                                                                          

  13\. Outcomes and prioritisation:\                                      3 (1)        430 (99)   Primary/main outcome(s) [\*](#TFN4){ref-type="other"}\      418 (97)   15 (3)     /
  List and define all outcomes\                                                                   specified as such                                                                 
  for which data will be sought,\                                                                                                                                                   
  including prioritisation of main\                                                                                                                                                 
  and additional outcomes, with\                                                                                                                                                    
  rationale                                                                                                                                                                         

  Primary/main outcome(s)\                                                235 (54)     198 (46)   /                                                                                 
  measure specified [\*](#TFN4){ref-type="other"}                                                                                                                                   

  Additional outcomes\                                                    430 (99)     3 (1)      /                                                                                 
  specified/ state None [\*](#TFN4){ref-type="other"}                                                                                                                               

  Additional outcomes:\                                                   131 (30)     180 (42)   122 (28)                                                                          
  measures specified [\*](#TFN4){ref-type="other"}                                                                                                                                  

  Rationale for choice of\                                                8 (2)        425 (98)   /                                                                                 
  outcome(s)                                                                                                                                                                        

  14\. Risk of bias in individual\                                        41 (9)       392 (91)   No risk of bias assessment\                                 4 (1)      3 (1)      426 (98)
  studies: Describe anticipated\                                                                  planned, and justification\                                                       
  methods for assessing risk of bias\                                                             provided                                                                          
  of individual studies, including\                                                                                                                                                 
  whether this will be done at the\                                                                                                                                                 
  outcome or study level, or both;\                                                                                                                                                 
  state how this information will be\                                                                                                                                               
  used in data synthesis [\*](#TFN4){ref-type="other"}                                                                                                                              

  Risk of bias tools named\                                               362 (84)     67 (16)    4 (1)                                                                             
  for all study types included                                                                                                                                                      

  Outcome or study level\                                                 310 (71)     119 (28)   4 (1)                                                                             
  or both                                                                                                                                                                           

  Domains/outcomes for risk\                                              342 (79)     87 (20)    4 (1)                                                                             
  of bias assessment stated                                                                                                                                                         

  Risk of bias assessment\                                                296 (68)     133 (31)   4 (1)                                                                             
  process described                                                                                                                                                                 

  How risk of bias findings\                                              64 (15)      365 (84)   4 (1)                                                                             
  will be used in the\                                                                                                                                                              
  synthesis                                                                                                                                                                         

  15a. Synthesis: Describe criteria\                                      200 (46)     233 (54)   Criteria for doing a\                                       131 (30)   233 (54)   69 (16)
  under which study data will be\                                                                 quantitative synthesis/\                                                          
  quantitatively synthesized                                                                      meta-analysis described [\*](#TFN4){ref-type="other"}                             

  15b. If data are appropriate for\                                       70 (16)      363 (84)   Summary measures [\*](#TFN4){ref-type="other"}              202 (46)   163 (38)   68 (16)
  quantitative synthesis, describe\                                                                                                                                                 
  planned summary measures,\                                                                                                                                                        
  methods of handling data, and\                                                                                                                                                    
  methods of combining data from\                                                                                                                                                   
  studies, including any planned\                                                                                                                                                   
  exploration of consistency (e.g.,\                                                                                                                                                
  I ^2^, Kendall's tau)                                                                                                                                                             

  Statistical method [\*](#TFN4){ref-type="other"}                        89 (20)      276 (64)   68 (16)                                                                           

  Use of fixed or random\                                                 194 (44)     171 (40)   68 (16)                                                                           
  effects or both [\*](#TFN4){ref-type="other"}                                                                                                                                     

  Data handling: conversion\                                              106 (24)     259 (60)   68 (16)                                                                           
  to same format                                                                                                                                                                    

  Data handling: missing\                                                 14 (3)       351 (81)   68 (16)                                                                           
  data                                                                                                                                                                              

  Combining data/\                                                        179 (41)     186 (43)   68 (16)                                                                           
  exploration of consistency                                                                                                                                                        

  Name of software to be\                                                 204 (47)     161 (37)   68 (16)                                                                           
  used for meta-analysis                                                                                                                                                            

  15c. Describe any proposed\                                             84 (19)      349 (81)   Subgroup analyses\                                          344 (79)   21 (5)     68 (16)
  additional analyses (e.g.,\                                                                     planned: co-variants\                                                             
  sensitivity or subgroup analyses,\                                                              named [\*](#TFN4){ref-type="other"}                                               
  meta-regression)                                                                                                                                                                  

  Methods for subgroup\                                                   25 (6)       280 (65)   128 (29)                                                                          
  analyses reported                                                                                                                                                                 

  Sensitivity analyses\                                                   85 (19)      280 (65)   68 (16)                                                                           
  planned                                                                                                                                                                           

  15d. If quantitative synthesis is not\                                  227 (52)     206 (48)   Descriptive, narrative,\                                    194 (45)   55 (12)    184 (43)
  appropriate, describe the type of\                                                              or qualitative synthesis\                                                         
  summary planned [\*](#TFN4){ref-type="other"}                                                   planned                                                                           

  Descriptive, narrative\                                                 49 (11)      200 (46)   184 (43)                                                                          
  or qualitative synthesis\                                                                                                                                                         
  methods described                                                                                                                                                                 

  Other analyses planned                                                  3 (1)        11 (3)     419 (96)                                                                          

  16\. Meta-bias(es): Specify any\                                        72 (17)      361 (83)   Publication bias to be\                                     94 (21)    271 (63)   68 (16)
  planned assessment of meta-\                                                                    assessed                                                                          
  bias(es) (e.g., publication bias\                                                                                                                                                 
  across studies, selective reporting\                                                                                                                                              
  within studies)                                                                                                                                                                   

  Outcome reporting bias to\                                              4 (1)        361 (83)   68 (16)                                                                           
  be assessed                                                                                                                                                                       

  17\. Confidence in cumulative\                                          37 (9)       396 (91)   Overall assessment of\                                      40 (9)     393 (91)   /
  evidence: Describe how the\                                                                     included studies planned                                                          
  strength of the body of evidence\                                                                                                                                                 
  will be assessed (e.g., GRADE)                                                                                                                                                    

  Methods specified                                                       38 (9)       395 (91)   /                                                                                 
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*\* Item/element required in PROSPERO \*Item/element identified in PROSPERO but as optional*

Scoring for 63 elements of the PRISMA-P items
---------------------------------------------

The score for some of the 19 items was reduced as a result of just one or two of the constituent elements being omitted from reports while others were relatively regularly identified.

Although overall the review question (item 7) was not found to contain all the expected elements, most did specify the elements of population (397, 92%) and the intervention (416, 96%) and just over half included the outcomes (237, 55%). The comparator was less frequently included (142, 33%); this may have been because of the intention of the review but where this was clear, the item was scored as not applicable (6%).

Information sources (item 9) was scored as completed in only two records (1%) overall; however, for the individual elements 431 (99%) did name the electronic databases to be searched, 289 (67%) said whether they planned to search study registries, and 238 (55%) indicated search dates. In item 10, provision of a draft search strategy (91, 21%) or search terms (100, 23%) was poor; but restrictions such as to English language papers were reported in 332 (77%).

Reporting of item 13, outcomes, scored badly overall (3, 1%) as, although the outcomes were included in most records (Primary 418, 97%; Secondary 430, 99%) only 8 (2%) were assessed as having provided a rationale for their choice of outcomes. Similarly, in item 14, the absence of information on how the risk of bias would be used in the synthesis, detracted from the high rate of inclusion of risk of bias tools and use. Reporting of the details for a quantitative synthesis, item 15b, had one element with a very low score (handling missing data, 14, 3%), the other six elements scored between 89 (20%) and 204 (47%).

In three items, the overall score reflected the general picture from the included elements. In item 6, rationale, both the reason for undertaking the review and the context were infrequently identified. PRIMSA-P items 16, meta-bias(es) and 17, confidence in cumulative evidence, were rarely reported. Only context is classified as optional information in PROSPERO, the remainder of these elements are not explicitly requested.

There appears to be a trend towards higher frequency of reporting of elements that are mandatory in PROSPERO, for example, in the eligibility criteria (item 8) and risk of bias (item 14). The trend is also seen in item 13, the required specification of primary and secondary outcomes, both frequently reported, but with a drop in specifying measures, which was optional.

Subgroup comparisons
--------------------

The subgroup comparisons investigated the stage of review at registration; whether or not information was reported on source of funding, sponsorship or support and where none was indicated; and whether or not the relevant box in the registration form had been ticked to indicate a meta-analysis was planned.

There were no differences in total scores for the 19 PRISMA-P items or the 63 elements, between those records registered before screening against eligibility criteria had started and those records registered after screening had commenced. This held true for the mean, standard deviation, median and range of scores.

A 6% difference was seen in the total score achieved for the meta-analysis (23%) vs no meta-analysis (29%) groups in the assessment of the 19 PRISMA-P items. The difference was reduced to 2% when considering the breakdown of 63 elements within the reported items (52% vs 54%). At both item and element level, the group of records with no planned meta-analysis scored slightly higher, but with a higher standard deviation from the mean and wider range of scores achieved.

Across all results for both the 19 items and 63 elements, the group with funding, sponsorship or support, scored slightly higher than those not receiving funding, sponsorship or support.

The results of the subgroups investigated are presented in [Table 3](#T3){ref-type="table"}. The subgroup scores by individual PRISMA-P reporting item are available on the OSF ( *Underlying data* ^[@ref-16]^).

###### Subgroup comparisons.

  --------------------------------------------------------------------------------------------------------------------------
  Subgroup                             Variable      No. of\   Total\      Total score\   Mean\        Median\   Range of\
                                                     records   possible\   achieved\      score\       score     scores
                                                               score       N (%)          (SD)                   
  ------------------------------------ ------------- --------- ----------- -------------- ------------ --------- -----------
  **Stage of review at**\              Before\       245       4655        1181 (25)      4.8 (1.9)    5         2--11
  **registration**                     screening\                                                                
                                       started                                                                   

  After screening\                     188           3572      900 (25)    4.8 (1.8)      4            2--10     
  started                                                                                                        

  **Meta-analysis planned**            M-A           250       4750        1088 (23)      4.4 (1.5)    4         2--9

  No M-A                               183           3477      993 (29)    5.4 (2.1)      5            2--11     

  **Funded / Sponsored /**\            Funded etc.   381       7239        1841 (25)      4.8 (1.9)    4         2--11
  **Supported**                                                                                                  

  Not funded etc.                      52            988       240 (24)    4.6 (1.6)      4            2--8      

  For 63 PRISMA-P reporting elements                                                                             

  **Stage of review at**\              Before\       245       15435       8214 (53)      33.5 (5.9)   33        18--47
  **registration**                     screening\                                                                
                                       started                                                                   

  After screening\                     188           11844     6255 (53)   33.3 (5.8)     33           21--47    
  started                                                                                                        

  **Meta-analysis**                    M-A           250       15750       8244 (52)      33.0 (5.2)   32        21--45

  No M-A                               183           11529     6225 (54)   34.0 (6.6)     34           18--47    

  **Funded / Sponsored /**\            Funded etc.   381       24003       12804 (53)     33.6 (5.9)   33        18--47
  **Supported**                                                                                                  

  Not funded etc.                      52            3276      1665 (51)   32.0 (5.3)     31           22--46    
  --------------------------------------------------------------------------------------------------------------------------

We present the scores by the 19 PRISMA-P items and by the breakdown of 63 elements for the ten countries and topics with the highest number of assessed records, and for number of authors listed in [Table 4](#T4){ref-type="table"}. None of these factors appear to have a marked influence on the number of PRISMA-P items or elements reported in PROSPERO records.

###### Overall scores by country, number of authors and topic of review.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                    No of\                             For the 19 PRISMA-P items assessed   For the 63 elements assessed                                               
                                                    records                                                                                                                                            
  ------------------------------------------------- ---------------------------------- ------------------------------------ ------------------------------ --- ------- ----------- ------------ ------ --------
  Australia                                         33                                 179 (28)                             5.4 (2.1)                      5   2--11   1115 (54)   33.8 (6.2)   32     21--47

  Brazil                                            53                                 272 (27)                             5.1 (1.9)                      5   2--9    1826 (55)   34.5 (6.0)   35     18--46

  Canada                                            37 [\*](#TFN5){ref-type="other"}   197 (28)                             5.3 (2.1)                      5   2--9    1301 (56)   35.2 (6.7)   35     21--45

  China                                             101                                418 (22)                             4.1 (1.3)                      4   2--10   3385 (54)   33.5 (4.5)   34     23--45

  England                                           46                                 259 (29)                             5.6 (2.2)                      5   2--10   1620 (55)   35.2 (6.9)   35.5   22--47

  Germany                                           11 [\*](#TFN5){ref-type="other"}   59 (28)                              5.4 (2.3)                      4   3--10   380 (55)    34.5 (6.2)   33     26--47

  Italy                                             15                                 71 (27)                              4.7 (1.8)                      4   3--9    499 (57)    33.3 (6.2)   32     24--47

  Netherlands                                       13                                 68 (28)                              5.2 (2.1)                      5   2--9    439 (53)    33.8 (7.0)   33     23--47

  Spain                                             13                                 64 (26)                              4.9 (1.8)                      4   2--7    426 (52)    32.8 (5.6)   33     22--42

  USA                                               48                                 242 (27)                             5.0 (2.2)                      4   2--10   1526 (51)   31.8 (6.4)   31     21--47

  Number of authors                                                                                                                                                                                    

  0--3                                              202                                956 (25)                             4.7 (1.8)                      4   2--10   6648 (52)   32.9 (5.9)   32     18--47

  4--6                                              179                                867 (25)                             4.8 (1.9)                      5   2--11   6008 (53)   33.6 (5.7)   34     21--47

  7+                                                52                                 258 (27)                             5.0 (1.9)                      4   2--9    1813 (56)   34.9 (5.9)   34     21--47

  Topic of review (10 with most assessed records)                                                                                                                                                      

  Cancer                                            42                                 184 (23)                             4.4 (1.8)                      4   2--10   1326 (50)   31.6 (5.6)   31     21--47

  Cardiovascular                                    58 [\*](#TFN5){ref-type="other"}   278 (25)                             4.8 (1.8)                      4   2--10   1952 (53)   33.7 (5.5)   33     21--46

  Complementary\                                    43                                 211 (26)                             4.9 (1.8)                      5   2--9    1511 (56)   35.1 (6.0)   36     22--44
  therapies                                                                                                                                                                                            

  Endocrine\                                        34 [\*](#TFN5){ref-type="other"}   175 (27)                             5.1 (2.1)                      5   2--10   1204 (56)   35.4 (6.1)   36     21--47
  and metabolic\                                                                                                                                                                                       
  disorders                                                                                                                                                                                            

  Mental health\                                    51                                 266 (27)                             5.2 (2.0)                      5   2--10   1762 (55)   34.5 (5.7)   33     21--44
  and behavioural\                                                                                                                                                                                     
  conditions                                                                                                                                                                                           

  Musculoskeletal                                   70                                 335 (25)                             4.8 (2.0)                      4   2--11   2295 (52)   32.8 (6.2)   32     18--47

  Neurological                                      42 [\*](#TFN5){ref-type="other"}   221 (28)                             5.3 (1.9)                      5   2--11   1443 (55)   34.4 (6.1)   33.5   23--47

  Physiotherapy                                     36                                 174 (25)                             4.8 (1.8)                      4   2--8    1194 (53)   33.2 (5.8)   32.5   18--43

  Rehabilitation                                    42 [\*](#TFN5){ref-type="other"}   201 (25)                             4.8 (2.1)                      4   2--11   1393 (53)   33.2 (5.7)   32.5   23--47

  Surgery                                           49                                 251 (27)                             5.1 (1.8)                      5   2--10   1644 (53)   33.6 (5.2)   33     23--47
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*\*numbers differ from [Table 1](#T1){ref-type="table"} because of the record(s) excluded at assessment*

Discussion
==========

Publication and registration of a systematic review protocol provides transparency in the review process, allowing readers to see the efforts made to minimise biases and where biases may still have influenced the final review findings. There is empirical evidence that few of the protocol registrations in PROSPERO have a corresponding published report ^[@ref-9]^. Where there is no protocol, the registration provides the only public record of what was originally planned. This study set out to establish to what extent PROSPERO registrations of systematic review protocols of healthcare interventions reported on items in the PRISMA-P reporting guidelines.

Using a random sample of 433 PROSPERO records from 2018, two researchers independently assessed the frequency of reporting of 19 PRISMA-P items, with 63 individual elements. The results show that while some key methodological details are relatively frequently reported, much of the information recommended in PRISMA-P is missing. Reporting was unsurprisingly more frequent for items that are mandatory in PROSPERO than those that are optional. Comparisons by stage of review at registration, whether meta-analysis was planned and whether funding or sponsorship was reported showed no meaningful differences between groups. The slight difference between groups with a planned meta-analysis or none may be because in PRISMA-P more details are specified for the reporting of a meta-analysis than for a descriptive, narrative or qualitative analysis.

Eligibility criteria and type of analysis planned were most frequently reported and are all separate required fields in PROSPERO. However, study selection process, which is optional, was also a higher frequency reported item. This may be explained by considering that some elements of items, such as eligibility criteria, study selection and risk of bias have what might be considered a standard, recognisable format that facilitates reporting. Other items need a more nuanced approach underpinned by a clear understanding of systematic review methods, and therefore may be associated with being less frequently reported due to a lack of confidence or experience with these aspects of review methods. For example, how risk of bias will be used in the synthesis, data handling in a meta-analysis, meta-biases and confidence in cumulative evidence, all had low scores. Part of the problem may be the uncertainty of what the searches will find when designing a systematic review but needing to know so the design is appropriate. For example, the intention may be to perform a meta-analysis, this may not be possible once the studies for inclusion have been identified. While, both PROSPERO and PRISMA-P acknowledge that protocols are iterative documents and may need to be amended, changes should be documented, justified and the stage of review at the time of the amendment made clear. Therefore, it is better to record alternative options for activities such as how data will be analysed and the conditions for selection of option when finalising the protocol.

Differences in frequency of reporting may also reflect where researchers considered items to be less or more important than others. For example, naming the software used for data management may not be seen as crucial, whereas the eligibility criteria and approach to synthesis are.

There are strengths and limitations to this study. The assessed sample of 433 records was representative of all the eligible 2018 non-Cochrane intervention reviews registered in PROSPERO. As a result, the findings may reasonably be generalised to other registrations of healthcare interventions, but not necessarily other types of registered reviews excluded from our sample.

PRISMA-P is a reporting guideline and not a rating scale, so judgements about whether sufficient information had been provided for some items carried a degree of subjectivity. The assessment guide and form developed for the study aimed to maximise objectivity but in accordance with PRISMA-P did not weight importance of items. Although two researchers independently carried out the assessments, achieving an overall agreement rate of 90%, subjectivity was minimised but not eliminated.

PROSPERO was developed in 2011 to record key protocol details and does not necessarily accord with everything subsequently recommended in the 2015 PRISMA-P reporting guidelines. Some registration items are mandatory and others optional. However, this study looked at records that had no other protocol output and arguably should therefore have provided PRISMA-P level detail. The evidence that protocol details are only available in PROSPERO for around 96% of non-Cochrane reviews makes the infrequency of reporting of items a concern ^[@ref-9],\ [@ref-10]^. Based on the findings of other studies, promoting improved reporting of protocol details may help increase the quality of systematic reviews ^[@ref-17],\ [@ref-18]^.

Protocols are iterative documents and even after a review has started there may be legitimate reasons for amendments. Such changes should and can be reported in a registration record, with their justification and timing. Just over two thirds of PROSPERO records have more than one version ( [Figure 1](#f1){ref-type="fig"}). While focussing on single entry records to be certain that any changes were not made after completion of the review this may have excluded records where more complete information was added to the record over time at key points in the review process.

This study simply looked at whether items were reported and not at the level of detail or suitability/appropriateness of the planned methods. The option of 'partially reported' could have been used at assessment but was avoided to minimise subjectivity. The focus was on simply establishing whether items were reported or not. The assessors focussed on whether the information was reported or could reasonably be inferred from what was reported. Assessing the quality of planned methods in protocol registrations needs to be the subject of further research.

This study shows that there is work to be done to promote the complete reporting of items recommended in the guidelines for systematic review protocols when the registration in PROSPERO is the only place they can be accessed. This is in line with other research that has identified issues with the quality of reporting, publication and outcome reporting biases in systematic review protocols in general ^[@ref-3],\ [@ref-9],\ [@ref-11],\ [@ref-13],\ [@ref-19],\ [@ref-20]^. As proposed in the PRISMA-P statement paper, actions and potential benefits to encourage adherence to PRISMA-P will take a joint effort on the part of a host of stakeholders, including reviewers, registries, and journal editors ^[@ref-5],\ [@ref-21]^.

Conclusions
===========

PROSPERO provides reviewers with the opportunity to be transparent in their planned methods and demonstrate efforts to reduce bias. However, where the PROSPERO record is the only available source of *a priori* reporting, there is a significant shortfall in the items reported, compared to those recommended in PRISMA-P. This presents peer reviewers and others wishing to assess the validity of the final review with challenges in interpretation. PROSPERO records are not peer reviewed or assessed for methodological quality, it is the responsibility of those registering their review to complete the registration form fully or provide access to a complete protocol. There are several areas requiring particular attention when completing the registration form. These include explaining the rationale for undertaking the review in the context of what is known; providing information sources beyond a list of databases to be searched; and reporting reproducible process methods for data management, study selection and risk of bias assessment. In addition, defining variables for data extraction, how specified outcomes will be measured, and the planned analyses, with criteria for undertaking a quantitative synthesis should all be included in detail.

This study only looked at whether recommended items were reported or not in PROSPERO records. Further research is needed to assess the quality of the planned methods in systematic review protocol registrations.

Data availability
=================

Underlying data
---------------

Open Science Framework: PROSPERO and PRISMA-P, <https://doi.org/10.17605/OSF.IO/7PW4G> ^[@ref-16]^.

Extended data
-------------

Open Science Framework: PROSPERO and PRISMA-P, <https://doi.org/10.17605/OSF.IO/7PW4G> ^[@ref-16]^.

This project contains the following underlying data: -Study protocol-Items, scoring options and guidance/rules for assessment of PROSPERO records compared to PRISMA-P reporting requirements

Data are available under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/legalcode) (CC-BY 4.0).

The authors would like to thank Fiona Rose for her assistance with the assessment of records.
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